Skip to content
PAD
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
PAD
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
Search
Read about Endologix
in the news
Embrace the evidence.
The Latest:
Jul 2
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
See Release
All News
Archives
All
2026
2025
2024
2023
2022
2021
Mar 3
Endologix Appoints Andrew Davis as Chief Commercial Officer
Jan 7
Endologix Announces Leadership Transition
Nov 5
Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session
Jun 18
Endologix Appoints Graham Phillips as Chief Operating Officer
May 13
One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
